Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction

Hypertension

Volumn 59, Issue 6, 2012, Pages 1164-1169

  Loan Le, Thi Yen ^a,b   Mardini, Mahidi ^a,b,d   Howell, Viive M ^c   Funder, John W ^e   Ashton, Anthony W ^c   Mihailidou, Anastasia S ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b Cardiology Division   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Apoptosis; Cardiovascular disease; Heart failure; Ischemia; Myocardial infarction; Reperfusion injury

Indexed keywords

ALDOSTERONE; APOPTOSIS REPRESSOR WITH CASPASE RECRUITMENT DOMAIN; CASPASE 2; CASPASE 3; CASPASE 8; CASPASE 9; CASPASE ACTIVATED DEOXYRIBONUCLEASE; EPLERENONE; LYSINE; PROTEASOME; SPIRONOLACTONE; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL NUCLEUS; CHROMATIN CONDENSATION; CONTROLLED STUDY; ENZYME ACTIVATION; EX VIVO STUDY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; RAT;

ALDOSTERONE ANTAGONISTS; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 2; CASPASE 3; CASPASE 9; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; IMMUNOBLOTTING; MALE; MUSCLE PROTEINS; MYOCARDIAL INFARCTION; PROTEOLYSIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SPIRONOLACTONE;

EID: 84861532245     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.190488     Document Type: Article

References (47)

1. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, Anderson JL, Anderson JL, Anderson JL, for the CORE Study Investigators. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol. 2002;39:30-36.
2. Kang PM, Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res. 2000;86:1107-1113.
3. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709-716.
4. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003; 16:925-930.
5. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study investigators. N Engl J Med. 1999;341:709-717.
6. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348: 1309-1321.
7. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
8. Adamopoulos C, Ahmed A, Fay R, Angioi M, Filippatos G, Vincent J, Pitt B, Zannad F, for the EPHESUS Investigators. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS Trial. Eur J Heart Failure. 2009;11: 1099-1105.
9. Schmidt K, Tissier R, Ghaleh B, Drogies T, Felix SB, Krieg T. Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion. Eur Heart J. 2010;31:1655-1662.
10. Chai W, Garrelds IM, de Vries R, Danser AHJ. Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone? Hypertension. 2006;47:665-670.
11. Mihailidou AS, Le TYL, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009;54:1306-1312.
12. Ekhterae D, Hinmon R, Matsuzaki K, Noma M, Zhu W, Xiao R-P, Gorman RC, Gorman JH. Infarction induced myocardial apoptosis and ARC activation. J Surgical Res. 2011;166:59-67.
13. Crow MT, Mani K, Mani K, Mani K, Kitsis RN. The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res. 2004;95:957-970.
14. Slee EA, Adrain C, Martin SJ. Serial killers: ordering caspase activation events in apoptosis. Cell Death Differ. 1999;6:1067-1074.
15. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420-427.
16. Takeda M, Tatsumi T, Matsunaga S, Hayashi H, Kimata M, Honsho S, Nishikawa S, Manoa A, Shiraishi J, Yamada H, Takahashi T, Matoba S, Kobara M, Matsubara H. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens Res. 2007;30:427-437.
17. Nam Y-J, Mani K, Ashton AW, Peng C-F, Krishnamurthy B, Hayakawa Y, Lee P, Korsmeyer SJ, Kitsis RN. Inhibition of both the extrinsic and intrinsic death pathways through nonhomotypic death-fold interactions. Mol Cell. 2004;15:901-912.
18. Donath S, Li P, Willenbockel C, Al-Saadi N, Gross V, Willnow T, Bader M, Martin U, Bauersachs J, Wollert KC, Dietz R, von Harsdorf R, for the German Heart Failure Network. Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and ischemic stress. Circulation. 2006;113:1203-1212.
19. Quadrilatero J, Bloemberg D. Apoptosis repressor with caspase recruitment domain is dramatically reduced in cardiac, skeletal, and vascular smooth muscle during hypertension. Biochem Biophys Res Comm. 2010;391:1437-1442.
20. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135.
21. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated dnase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391:43-50.
22. Sahara S, Aoto M, Eguchi Y, Imamoto N, Yoneda Y, Tsujimoto Y. Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation. Nature. 1999;401:168-173.
23. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388:300-304.
24. Cory S, Adams JM. The Bcl2 family: regulators of the cellular lifeor-death switch. Nat Rev Cancer. 2002;2:647-656.
25. Nam Y-J, Mani K, Wu L, Peng C-F, Calvert JW, Foo RS-Y, Krishnamurthy B, Miao W, Ashton AW, Lefer DJ, Kitsis RN. The apoptosis inhibitor ARC undergoes ubiquitin-proteasomal-mediated degradation in response to death stimuli: identification of a degradation-resistant mutant. J Biol Chem. 2007;282:5522-5528.
26. Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, Richard V, Renet S, Henry JP, Jeng AY, Webb RL, Thuillez C. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J. 2008;29:2171-2179.
27. Barbato JC, Mulrow PJ, Shapiro JL, Franco-Saenz R. Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension. 2002;40:130-135.
28. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki L-M. Apoptosis in human acute myocardial infarction. Circulation. 1997;95:320-323.
29. Burniston JG, Saini A, Tan L-B, Goldspink DF. Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. J Mol Cell Cardiol. 2005;39:395-399.
30. De Angelis N, Fiordaliso F, Latini R, Calvillo L, Funicello M, Gobbi M, Mennini T, Masson S. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol. 2002;34:1655-1665.
31. Mano A, Tatsumi T, Shiraishi J, Keira N, Nomura T, Takeda M, Nishikawa S, Yamanaka S, Matoba S, Kobara M, Tanaka H, Shirayama T, Takamatsu T, Nozawa Y, Matsubara H. Aldosterone directly induces myocyte apoptosis through calcineurindependent pathways. Circulation. 2004;110:317-323.
32. Mihailidou AS, Mardini M, Fraser T, Funder JW. Agonist/antagonist activity of cortisol in cardiomyocyte mineralocorticoid receptors is determined by redox state. Presented at the 30th Meeting of the International Aldosterone Conference; June 14-15, 2004; New Orleans, LA.
33. Almeida OFX, Conde GL, Crochemore C, Demeneix BA, Fischer D, Hassan AHS, Meyer M, Holsboer F, Michaelidis TM. Subtle shifts in the ratio between pro-and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J. 2000;14:779-790.
34. Abbate A, Biondi-Zoccai GGL, Bussani R, Dobrina A, Camilot D, Feroce F, Rossiello R, Baldi F, Silvestri F, Biasucci LM, Baldi A. Increased myocardial apoptosis in patients with unfavorable left ventricular remodelling and early symptomatic post-infarction heart failure. J Am Coll Cardiol. 2003;41:753-760.
35. Mani K. Programmed cell death in cardiac myocytes: strategies to maximize post-ischemic salvage. Heart Fail Rev. 2008;13:193-209.
36. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 1998;391: 96-99.
37. Liu X, Li P, Widlak P, Zou H, Luo X, Garrard WT, Wang X. The 40-kda subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc Natl Acad Sci USA. 1998;95:8461-8466.
38. Misao J, Hayakawa Y, Ohno M, Kato S, Fujiwara T, Fujiwara H. Expression of Bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation. 1996;94:1506-1512.
39. Ludwig-Galezowski A, Flanagan L, Rehm M. Apoptosis repressor with caspase recruitment domain, a multifunctional modulator of cell death. J Cell Mol Med. 2011;15:1044-1053.
40. Zhang YQ, Herman B. ARC protects rat cardiomyocytes against oxidative stress through inhibition of caspase-2 mediated mitochondrial pathway. J Cell Biochem. 2006;99:575-588.
41. Gustafsson AB, Sayen MR, Williams SD, Crow MT, Gottlieb RA. TAT protein transduction into isolated perfused hearts: TAT-apoptosis repressor with caspase recruitment domain is cardioprotective. Circulation. 2002;106:735-739.
42. McCully JD, Wakiyama H, Hsieh YJ, Jones M, Levitsky S. Differential contribution of necrosis and apoptosis in myocardial ischemiareperfusion injury. Am J Physiol Heart Circ Physiol. 2004;286: H1923-H1935.
43. Scarabelli TM, Stephanou A, Pasini E, Comini L, Raddino R, Knight RA, Latchman DS. Different signaling pathways induce apoptosis in endothelial cells and cardiac myocytes during ischemia/reperfusion injury. Circ Res. 2002;90:745-748.
44. Foo RS-Y, Chan LKW, Kitsis RN, Bennett MR. Ubiquitination and degradation of the anti-apoptotic protein ARC by MDM2. J Biol Chem. 2007;282:5529-5535.
45. Nakamura Y, Suzuki S, Ono K, Miura I, Satoh F, Moriya T, Saito H, Yamada S, Ito S, Sasano H. MDM2: a novel mineralocorticoidresponsive gene involved in aldosterone-induced human vascular structural remodelling. Am J Path. 2006;169:362-370.
46. Sohn HJ, Yoo KH, Jang GY, Lee JH, Choi BM, Bae IS, Yim HE, Son CS, Lee JW. Aldosterone modulates cell proliferation and apoptosis in the neonatal rat heart. J Korean Med Sci. 2010;25:1296-1304.
47. McCullers DL, Herman JP. Mineralocorticoid receptors regulate bcl-2 and p53 mRNA expression in hippocampus. Neuroreport. 1998;9: 3085-3089.